Bortezomib (PS-341)

Catalog No.S1013 Synonyms: LDP-341, MLM341

Bortezomib (PS-341) Chemical Structure

Molecular Weight(MW): 384.24

Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM in a cell-free assay.

Size Price Stock Quantity  
USD 70 In stock
USD 270 In stock
USD 670 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 142 Publications

20 Customer Reviews

  • Effect of different proteasome inhibitors on dysferlin expression and on membrane resealing in cultured primary myoblasts. Primary myoblasts from patient 2 harboring a homozygous Arg555Trp DYSF mutation that were treated with the indicated amounts of bortezomib for 24 hours. Western blots of protein extracts were stained with anti-dysferlin antibodies and with anti–a-tubulin antibody as loading control.

    Sci Transl Med 2015 6(250), 250ra112. Bortezomib (PS-341) purchased from Selleck.

    Pharmacologic inhibition of the proteasome blocks proplatelet formation in murine and human megakaryocytes. Human megakaryocytes were pretreated with vehicle or bortezomib, and megakaryocytes producing proplatelets (PP) were examined. Shown are representative transmission images and representative confocal images with wheat germ agglutinin (WGA; red) and phalloidin (green) staining. Scale bars: 50 um.

    J Clin Invest 2014 124(9), 3757-66. Bortezomib (PS-341) purchased from Selleck.

  • Immunofluorescence showing HDAC4 localization in mouse primary osteoblasts treated with vehicle or PTH alone or in the presence of bortezomib. Primary osteoblasts treated with vehicle, PTH, or PTH plus bortezomib for 2 h using anti-HDAC4 and anti-b-actin antibodies.

    J Cell Biol 2014 205(6), 771-80. Bortezomib (PS-341) purchased from Selleck.

    Effects of NF-kB inhibition on cell proliferation and apoptosis in Foxp3cKO prostate. A. Top left panels: Representative H&E staining of PIN lesions in ventral prostates of 60-week-old PBS- or bortezomib-treated Foxp3cKO littermates. Scale bar, 50 祄. Right graph: Quantification of Ki67-positive cells identified by IHC analysis (bottom left panels) as a measure of cell proliferation, performed with Scion Image software. Horizontal lines represent the average values. The p value was determined by two-tailed t test. B. Representative western blots showing p65 and nuclear p65 (N-p65) expression in prostates at 12 hours after LPS injection in 45-week-old PBS- or bortezomib-treated mice. C. Quantification of Bcl2l1 and Traf1/2 mRNA expression as a percentage of Hprt expression measured in microdissected mouse prostate epithelial cells by qPCR at 12 hours after LPS injection in 45-week-old PBS- or bortezomib-treated mice. Horizontal lines represent the average values. The p values were determined by two-tailed t test. D. Left panels: Representative images of TUNEL assays performed on prostates from PBS- or bortezomib-treated mice at 60 weeks of age. Insets show the apoptotic cells (green) in prostate glands. Scale bar, 100 祄. Right graph: Quantification of apoptotic cells in the ventral and dorsolateral prostates of PBS- or bortezomib-treated mice at 45 and 60 weeks of age. Horizontal lines represent the average values. The p value was determined by two-tailed t test. cKO, PB4-Cre4+Foxp3flox/y; wks, weeks; B/P, ratio of the mean value from bortezomib-treated mice to the mean value in PBS-treated mice. All experiments were repeated two times. Wks, weeks.

    Cancer Res 2015 75(8), 1714-24. Bortezomib (PS-341) purchased from Selleck.

  • Inhibition of proteasome and lysosome or silencing of VCP and co-factors lead to the accumulation of OP-puro-labeled DRIPs adjacent to or within SGs. HeLa cells were co-treated for 45 min with OP-puro and arsenite (Ars.); where indicated, cells were pretreated with bortezomib (Bort.) overnight and/or ammonium chloride (NH4Cl) for 2 h 15 min. Cells were fixed and labeled with Alexa594-Azide and anti-TIA-1.

    Cell Death Differ 2014 21(12), 1838-51. Bortezomib (PS-341) purchased from Selleck.

    Control wild-type and Fmn2–/–oocytes observed at different stages of meiotic maturation [prophase I (Pro I), NEBD, 3 hours and 8 hours after NEBD] using anti-Fmn2. wt + Bortezo, wild-type oocytes treated with 0.1μM Bortezomib for 90 minutes before fixation. All oocytes were observed using the same settings and the images treated the same way (three independent experiments). Red arrows indicate cortical labeling. Scale bar: 10μm.

    Development 2011 138, 2903-2908. Bortezomib (PS-341) purchased from Selleck.

  • Immunofluorescence analysis for Ser536 p-NF-κB cellular localization of RS4;11cells treated with CX-4945 (5 μM) and bortezomib (2.5 nM) either alone or in combination. Cells were treated, collected at 22 h and reacted with an antibody to Ser536 p-NF-κB which was revealed by a Cy3-conjugated secondary antibody. DAPI was used to label nuclei.

    Oncotarget, 2015, 51: S659-S660. Bortezomib (PS-341) purchased from Selleck.

    (B–C) LNCaP (B) and LNCaP-AI (C) cells were transiently transfected with sPLA2-IIa(-800)-Luc (0.5 μg). The cells were then treated with Erlotinib (20 μM), Gefitinib (20 μM), Lapatinib (20 μM), CI-1033 (8 μM), LY294002 (20 μM) and Bortezomib (20 μM) without or with EGF (100 ng/ml) for 24 h. Luciferase assay was performed according to a standard protocol with Renilla luciferase as an internal control. Data are presented as the mean (±SD) of duplicate values of a representative experiment that was independently repeated for five times.

    Carcinogenesis 2010 31, 1948–1955. Bortezomib (PS-341) purchased from Selleck.

  • LNCaP-AI cells were starved in 1% stripped medium for 24 h. The cells were then treated with Erlotinib (20 μM), Gefitinib (20 μM), Lapatinib (20 μM), CI-1033 (8 μM), LY294002 (20 μM) and Bortezomib (20 μM) for 24 h. Cell culture medium was collected from each sample and subjected to ELISA for sPLA2-IIa. The condition medium samples were diluted 10 times for ELISA. Average of duplicate samples was converted to nanogram per milliliter against standard curve. The data represent one of five repeated experiments.

     

     

    Carcinogenesis 2010 31, 1948–1955. Bortezomib (PS-341) purchased from Selleck.

    The stable cell line HepAD38 was incubated for 18 h in the presence of the indicated amount of Bortezomib. The medium was removed and replaced by medium containing Bortezomib dissolved in PBS. In case of the control cells the same amount of PBS was added to the medium. 4 h later this procedure was repeated and again 14 h later the supernatant was collected. The amount of viral particles was quantified by real time PCR. HBV-genome quantification was done using COBAS® AmpliPrep/COBAS® TaqMan® HBV test (Roche Diagnostics GmbH, Mannheim, Germany) according to the manufacturer’s instructions. The assay shows relative values (the value for untreated control cells was arbitrarily set as 1) that are based on three independent experiments. The cell viability was analyzed by MTT assays. For does up to 50 nM no significant effect on cell viability was observed within 18h, for 100 nM the proportion of metabolically active cells was reduced to 83%.

    J Biol Chem 2010 285, 41074-41086. Bortezomib (PS-341) purchased from Selleck.

  • Western blot of extracts of infected cells treated with different proteasome inhibitors at different concentrations, reacted with the indicated antibodies. p53 was used to monitor proteasome inhibition, and actin was used as a loading control.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

    Time window treatment with proteasome inhibitors. (A) Scheme of the experiment performed with MA104 cells exposed to virus (OSU; MOI, 3) for 1 h and analyzed at the starting point and endpoint of the indicated time window treatments with DMSO, MG132, or bortezomib. (B) Western blot of cellular lysates derived from cells infected for the indicated time periods and treated with the proteasome inhibitors or DMSO. NI, noninfected cells. Blots were reacted with the indicated antibodies; p53 was used to monitor proteasome inhibition, and actin was used as a loading control.

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

  • Fluorescence analysis of viroplasm formation on NSP5-EGFP cells infected with rotavirus (OSU; MOI, 3) and treated or not treated with MG132 (10 M) or bortezomib (10 M) at different times p.i., as indicated. Cells were analyzed at the starting points (1 h, 3 h, 5 h, 7 h) and endpoints (9 h) of the inhibitor’s window treatment.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

    Quantification of the accumulation of viroplasms in infected NSP5 -EGFP/MA104 cells. At different times p.i., cells were treated for 4 h with DMSO or the indicated proteasome inhibitor and the number of viroplasms/cell was quantified at the starting (1 h, 3 h, 5 h; white bars) and endpoints (5 h, 7 h, 9 h) of treatment.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

  • PS-341 impairs FPV replication in A549 cells. (A and B)A549 cells were either pretreated for 1 h with different concentrations of PS-341 or with solvent only or were left untreated. Then, cells were infected with FPV at an MOI of 0.001 (A) or 0.05 (B). After virus inoculation cells were posttreated with different concentrations of PS-341. (A) At 24 h p.i. supernatants were obtained and progeny virus titers were measured by standard plaque assay. (B)Proteasome activity and the ability of PS-341 to inhibit the proteasome was determined 24 h p.i. (C) A549 cells were pretreated with 50 nM PS-341 or solvent or left untreated for 1 h. Afterwards cells were infected with FPV at an MOI of 0.0005. Subsequent to virus inoculation cells were posttreated with 50 nM PS-341 or solvent or left untreated. After the indicated times p.i.supernatants were obtained and progeny virus titers were determined by standard plaque assay. Arrow bars in all experiments represent standard deviations of three independent experiments.

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

    Early steps of viral replication within the first replication cycle are affected. (A) For time-of-addition kinetics analysis, A549 cells were either left untreated or were pretreated for 10 h or 1 h with 50 nM PS-341 before infection and additionally posttreated after infection. Cells were infected with FPV at an MOI of 0.005. After virus inoculation cells were posttreated with 50 nM PS-341. Then the proteasome inhibitor was added after virus inoculation (10 h, 1 h, and 30 min) or it was added at the different times p.i. as indicated (1 h, 2 h, 4 h, 6 h, and 8 h; cells were not pretreated before infection). At 9 h p.i. supernatants were obtained and progeny virus titers were determined by standard plaque assay. Shown is one representative experiment out of three independent experiments. (B) A549 cells were pretreated with 50 nM PS-341 or left untreated for 1 h. Afterwards cells were infected with avian FPV or human PR8 at an MOI of 1. Subsequent to virus inoculation cells were posttreated with 50 nM PS-341 or left untreated. After the indicated times p.i. cells were lysed and analyzed by Western blotting for accumulation of viral proteins polymerase PB1 and matrix protein M1. Cellular protein ERK2 served as a control to demonstrate equal amounts of protein loading. Shown is one representative blot out of three independent experiments.

     

     

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

  • A549 cells were treated with PS-341 at 50 nM for the indicated times or left untreated. Western blotting was performed with total cell lysates, using phospho-specific antibodies against JNK and the transcription factors c-Jun and ATF-2 or loading controls, respectively.

     

     

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

    Proteasome inhibition effect on biotinylation of MHC-Iα. (a) WB-ra of cellular extracts of HEK293 cells co-transfected with BAP-MHC-Ia and cyt-BirA (control) and, where indicated, with US2 or US11 in the absence (2) or presence of MG132 (MG; 50 μM for 4 h) or Bortezomib(Bort.; 50 μM for 4 h).

    PLoS One 2011 6, e23712. Bortezomib (PS-341) purchased from Selleck.

  •  

    KKU-M213 was treated with BTZ as indicated. Total cell lysate ( a) and nuclear extract (b) were prepared. Actin and γ -tubulin were loading controls for total and nuclear proteins, respectively.

    2011 Mireia Vila Gasull University of Porto. Bortezomib (PS-341) purchased from Selleck.

    Mireia Vila Gasull University of Porto. 2011;Mireia Vila Gasull . Bortezomib (PS-341) purchased from Selleck.

Purity & Quality Control

Choose Selective Proteasome Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM in a cell-free assay.
Targets
20S proteasome [1]
(Cell-free assay)
0.6 nM(Ki)
In vitro

Bortezomib, a boronic acid dipeptide, is a highly selective, reversible inhibitor of the 26S proteasome which primarily functions in the degradation of mis-folded proteins and is essential for the regulation of the cell cycle. Exposure to Bortezomib has been shown to stabilize p21, p27, and p53, as well as the proapoptotic Bid and Bax proteins, caveolin-1, and inhibitor κB-α, which prevents activation of nuclear factor κB-induced cell survival pathways. Bortezomib also promotes the activation of the proapoptotic c-Jun-NH2 terminal kinase, as well as the endoplasmic reticulum stress response. Alteration of the levels of these cellular proteins leads to inhibition of proliferation, migration, and promotion of apoptosis of cancer cells. [2] Bortezomib is shown to penetrate into cells and inhibit proteasome-mediated intracellular proteolysis of long-lived proteins with a concentration that inhibits 50% of the proteolysis of ∼0.1 μM. The average growth inhibition of 50% value for Bortezomib across the entire panel of 60 cancer cell lines derived from multiple human tumors from the US National Cancer Institute (NCI) is 7 nM. Treatment of PC-3 cells with Bortezomib (100 nM) for 8 h results in the accumulation of cells in G2-M, with a corresponding decrease in the number of cells in G1. Bortezomib kills PC-3 cells at 24 and 48 hr with IC50 of 100 and 20 nM, respectively. Bortezomib induces nuclear condensation at 16–24 hr after treatment. Bortezomib treatment leads to PARP cleavage in a time-dependent manner with concentrations as low as 100 nM being effective at 24 hr. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF-7 M1HBXmN6fG:2b4jpZ{BCe3OjeR?= MYe1NEDPxE1? MVi0PEBp NUXUSYROTE2VTx?= NYLie5U3U2mubIOgZ4VtdHNiYomgcY9z\SC2aHHuJFk6LQ>? NV7zW2V4OTB2OUm2OFM>
OVCA 429 M1jjfmZ2dmO2aX;uJGF{e2G7 M1jXblMxOCCwTR?= NGLh[2w1QCCq M3:0XGROW09? MkDMSIl{enWydIOgbY51[WO2IH31cJRq[2WubIXsZZIhfHWvb4Kgd5Bp\XKxaXTz MWGxNFk6QTd4Nh?=
RPMI8226 M{LweGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;0dFlIOTByIH7N NF;ycmg1QCCq MlHsSG1UVw>? Moi2TWM2OD1|MDDuUS=> NYPH[Wl3OTF|ME[0PFk>
Dox40 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jaNFExOCCwTR?= Mnu0OFghcA>? NELnfmxFVVOR MmH6TWM2OD12MDDuUS=> MV[xNVMxPjR6OR?=
MR20 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXmxNFAhdk1? NIn1[YI1QCCq MkLuSG1UVw>? MX\JR|UxRTJyIH7N NXjrWYwyOTF|ME[0PFk>
LR5 NFHmNlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\Ob4kyODBibl2= MnnROFghcA>? MYXEUXNQ MUTJR|UxRTJyIH7N MkfHNVE{ODZ2OEm=
U266 MmjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{KxWFExOCCwTR?= NWTPWHhVPDhiaB?= MX7EUXNQ NHLOWItKSzVyPUOgcm0> NGXLN4syOTNyNkS4PS=>
IM-9 M{\4dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPBb3Z{OTByIH7N MYK0PEBp NUPzOYRFTE2VTx?= NUnwdJFyUUN3ME22JI5O NGjQSZcyOTNyNkS4PS=>
Hs Sultan MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rOOVExOCCwTR?= NUXyRo9NPDhiaB?= M2m3bGROW09? MnXITWM2OD1{MDDuUS=> M4TvUlEyOzB4NEi5
PAM-LY2 NIq1cJRHfW6ldHnvckBCe3OjeR?= M2q0WlExOCCwTR?= MmjCNVIhcA>? M2LTZ2ROW09? M331W2lvcGmkaYTzJG5HNc78QjDhZ5RqfmG2aX;u MmX5NVE{PTB7MUO=
PAM 212 M2TadWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXKxNFAhdk1? NH6xSZE4OiCq NUXqeGFHTE2VTx?= NHjQWY1KdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?= MYCxNVM2ODlzMx?=
PAM-LY2 M135b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYWxNFAhdk1? MkXsO|IhcA>? MojQSG1UVw>? MVPJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>? M1LpeVEyOzVyOUGz
B4B8 Mo\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fiZlExOCCwTR?= M336O|czKGh? NXyxdXl4TE2VTx?= Mmn3TY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl? M1e2WFEyOzVyOUGz
B7E3 M4nXW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWmyfm4xOTByIH7N M3HrblczKGh? Ml;qSG1UVw>? NYX4cHlqUW6qaXLpeJMh[2WubDD2bYFjcWyrdIm= MlnrNVE{PTB7MUO=
UM-SCC-9 NVPxd5M1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fiWlExOCCwTR?= NHTNfVg4OiCq M2\6VGROW09? NWHrfYZUUW6qaXLpeJMh[2WubDD2bYFjcWyrdIm= MUmxNVM2ODlzMx?=
UM-SCC-11B M4PqUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfRNVAxKG6P MoTEO|IhcA>? M4TGNGROW09? NUnUZ2NXUW6qaXLpeJMh[2WubDD2bYFjcWyrdIm= MnrQNVE{PTB7MUO=
H460 MkfYSpVv[3Srb36gRZN{[Xl? M{TLXVExKM7:TR?= M4\KelI1KGh? MV;EUXNQ M3H1UGlv\HWlZYOgRoNtNTJicHjvd5Bpd3K7bHH0bY9vKGGwZDDjcIVifmGpZTDjc5Jz\WyjdHXkJJdqfGhiR{KtUUBxcGG|ZTDhdpJme3R? NYDZVW42OTJ2OUKxNVc>
U266 NGPOeW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;FN5c2PTByIH7nM41t NYexNGI3PDhiaB?= NVmxRZM3TE2VTx?= NWTwdIFpUW6qaXLpeJMh[2WubDDndo94fGh? NFHk[nQyOjZ|MU[xPS=>
ARH77 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLV[5h7PTByIH7nM41t MVG0PEBp NFnJN3NFVVOR NGHZOJRKdmirYnn0d{Bk\WyuIHfyc5d1cA>? MVGxNlY{OTZzOR?=
WAD-1 M{G2cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHK[Gk2ODBibnevcYw> NHf2WFI1QCCq MojzSG1UVw>? MY\Jcohq[mm2czDj[YxtKGe{b4f0bC=> MVixNlY{OTZzOR?=
U266/LR7 MmjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLrUWtWPTByIH7nM41t M2jaflQ5KGh? MXrEUXNQ NWPi[ZpmUW6qaXLpeJMh[2WubDDndo94fGh? MXixNlY{OTZzOR?=
U266/dox4 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXi1NFAhdmdxbXy= Ml3WOFghcA>? NYPqdHM3TE2VTx?= MUTJcohq[mm2czDj[YxtKGe{b4f0bC=> MnuyNVI3OzF4MUm=
RPMI8226/LR5 NGDUV3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYS1NFAhdmdxbXy= MVe0PEBp Mn7ISG1UVw>? MWTJcohq[mm2czDj[YxtKGe{b4f0bC=> NWrXWGk3OTJ4M{G2NVk>
H460 NV\YU2NjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWOxNEDPxE1? NHjhOFU4OiCq NVfYdmZGTE2VTx?= NVuyW5N3UUN3ME2xNFAhdk1? NUnQNohQOTJ4M{G2NlA>
H358 NF:5Nm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PERlExKM7:TR?= NWGxZ2J5PzJiaB?= Mof3SG1UVw>? M1HLbGlEPTB;N{Cgcm0> NVy0N4d7OTJ4M{G2NlA>
H322 Mn;sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXuxNEDPxE1? NEHKW3c4OiCq NY\McodWTE2VTx?= Mlr2TWM2OD14MkCgcm0> M{HTdVEzPjNzNkKw
H460 MWHGeY5kfGmxbjDBd5NigQ>? NYiwcIJSOTByIH7N NHX2eZQzPCCq NYjoWJpzTE2VTx?= MnjtTY5lfWOnczDHNk1ONXCqYYPlJIFzemW|dDDhcoQhfHWkdXzpckBie3OnbXLsfU1lcXOjc4PlcYJtgQ>? MVSxNlY{OTZ{MB?=
LNCap-Pro5 M1zCcGZ2dmO2aX;uJGF{e2G7 M2r3RlEh|ryP MVm0JIg> NVi3VJlbTE2VTx?= MlzhV5Ri[mmuaYrld{BxPTN? MWmxOFYyOjV|Mh?=
T29 M4\tcGFxd3C2b4Ppd{BCe3OjeR?= M2nSVFUxKG6P Ml3JOFghcCB? M{jofWROW09? NW\GNGRnUW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NV:ybYNMOTZ5N{ixO|k>
T29Kt1 NIfzU4xCeG:ydH;zbZMhSXO|YYm= MonHOVAhdk1? Mnr3OFghcCB? NFXNUoNFVVOR M4PCPGlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MmT2NVY4PzhzN{m=
HCT116 M4jsfGFxd3C2b4Ppd{BCe3OjeR?= M121UFUxKG6P NX;VV29KPDhiaDC= NXjXeZFJTE2VTx?= MVfJcoR2[2W|IHPlcIwh[XCxcITvd4l{ MY[xOlc4QDF5OR?=
HKe-3 NE\Cc5ZCeG:ydH;zbZMhSXO|YYm= MVq1NEBvVQ>? NFjHPI01QCCqIB?= MVLEUXNQ NUmzWo46UW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= M2nCflE3Pzd6MUe5
NB-1691 MkO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrBeWV{OSEQvF2= Ml7CO|IhcA>? MmfmTY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJJRwKDVn Ml7CNVc3QDl4OES=
CHLA-255 MnjMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGK5b|YyKM7:TR?= NYLySVY6PzJiaB?= NUnJOFJkUW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKHSxIEKl NXTHT4Q5OTd4OEm2PFQ>
SK-N-AS MmXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mof6NUDPxE1? M1zQfVczKGh? NXzDdYZ1UW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKHSxIEGwKS=> MlXLNVc3QDl4OES=
NB-1691 M2HYVmZ2dmO2aX;uJGF{e2G7 NXnZWm01OTBibl2= NYDp[ZhkOjRiaB?= MXrTbYdvcW[rY3HueIx6KHKnZIXj[ZMh[2WubIOgbY4hfGinIFewM2cyKHCqYYPl MUKxO|Y5QTZ6NB?=
CHLA-255 MmSzSpVv[3Srb36gRZN{[Xl? NH6yWHMyOCCwTR?= M1fpXlI1KGh? NFLa[YdOd2Snc4TsfUBz\WS3Y3XzJINmdGy|IHnuJJRp\SCJMD;HNUBxcGG|ZR?= NXv4NYd1OTd4OEm2PFQ>
RPMI 8226 M4PKcGZ2dmO2aX;uJGF{e2G7 MUmyNEBvVQ>? MmPRPEBp MmWwV4lodmmoaXPhcpRtgSCnbnjhcoNmeyCQRj5OvmIh[WO2aY\peJk> MVixPVQ{PjB3MB?=
MM.1S M17XUGZ2dmO2aX;uJGF{e2G7 Mk\SNlAhdk1? NXTDd49vQCCq NEe5UIVUcWewaX\pZ4FvfGy7IHXubIFv[2W|IF7GMe67SiCjY4Tpeol1gQ>? MUSxPVQ{PjB3MB?=
U266 MVPGeY5kfGmxbjDBd5NigQ>? NIDIXWgzOCCwTR?= Mn\KPEBp M2HoN3Nq\26rZnnjZY51dHliZX7oZY5k\XNiTl[t{tpDKGGldHn2bZR6 M2PPbVE6PDN4MEWw
OPM1 NGfEd4hHfW6ldHnvckBCe3OjeR?= NFXuO5kzOCCwTR?= MmnlPEBp NF7yWW1UcWewaX\pZ4FvfGy7IHXubIFv[2W|IF7GMe67SiCjY4Tpeol1gQ>? NVThfZVkOTl2M{[wOVA>
INA6 NHOzbFZHfW6ldHnvckBCe3OjeR?= NUDXW2JxOjBibl2= MXq4JIg> Mm\UV4lodmmoaXPhcpRtgSCnbnjhcoNmeyCQRj5OvmIh[WO2aY\peJk> Mn7iNVk1OzZyNUC=
OPM2 MV7GeY5kfGmxbjDBd5NigQ>? MX2yNEBvVQ>? M1;BWFghcA>? MX3TbYdvcW[rY3HueIx6KGWwaHHuZ4V{KE6ILd86RkBi[3Srdnn0fS=> MUCxPVQ{PjB3MB?=
RPMI 8226 MkfwSpVv[3Srb36gRZN{[Xl? M1\jfVIxKG6P MmrlPEBp NFPQVVhKdmS3Y3XzJGRPSSC|eX70bIV{cXN? NHzBPFYyQTR|NkC1NC=>
BaF/3 NFSybY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELSVFMyODBibl2= NGezcG41QCCq MnTITWM2OD14LkKgcm0> MXWyNFMxPTZ7Mh?=
BaF/3-p210 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoW3NVAxKG6P NHrXU3Q1QCCq MW\JR|UxRTRwNzDuUS=> MnLDNlA{ODV4OUK=
TCC-S M17sNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUWxNFAhdk1? MXG0PEBp Mn:1TWM2OD1{Lkigcm0> NXTweZFEOjB|MEW2PVI>
BaF/3 MnzrSpVv[3Srb36gRZN{[Xl? MkHVOkBvVQ>? NGnDN401QCCq M1;OZ2lv\HWlZYOgZUBoemWjdDDHNUBk\WyuLXP5Z4xmKGG{cnXzeC=> MVmyNFMxPTZ7Mh?=
BaF/3-p210 MWDGeY5kfGmxbjDBd5NigQ>? NELMVlc3KG6P NH\KdVM1QCCq MoXvTY5lfWOnczDhJJNtcWeqdDDHNUBk\WyuLXP5Z4xmKGG{cnXzeC=> MYWyNFMxPTZ7Mh?=
BaF/3-p210 MojFSpVv[3Srb36gRZN{[Xl? MmP6OkBvVQ>? M{TsPFI1KGh? M2Ltd3Jm\HWlZYOgeIhmKHCqb4PwbI9zgWyjdHnvckBidmRidHjlJIFkfGm4aYT5JI9nKFKk MoP0NlA{ODV4OUK=
Raji NVXmRnJHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TnZVEh|ryP NGO5cpgzPCCq MXfS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? NETPVIwzOTF5MEm4PC=>
LCL-1 Mmi5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXr6SVVpOSEQvF2= MWiyOEBp M1WzRnJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= MlHkNlEyPzB7OEi=
LCL-2 MnjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPSSWkyKM7:TR?= NGTDOXQzPCCq MnrmVoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi MkjWNlEyPzB7OEi=
BJAB M3rVOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrkNUDPxE1? NHnlfmwzPCCq NFT4b4NT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= M3XQWlIyOTdyOUi4
SNT-13 M{O2RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLuRWd[OSEQvF2= NW\sbI9mOjRiaB?= NFexe3pT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= M4HEcFIyOTdyOUi4
SNT-16 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1noRlEh|ryP NXjtOGhTOjRiaB?= NI\lZ3FT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= NXnVXmE4OjFzN{C5PFg>
Jurkat NHfkTo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPiNUDPxE1? M2fRUFI1KGh? MXLS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? M{\lUFIyOTdyOUi4
KAI-3 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XJPVEh|ryP NX3yWYp2OjRiaB?= NI\JOFNT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= MnPNNlEyPzB7OEi=
SNK-6 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjweXkyKM7:TR?= MnzjNlQhcA>? NVzLfVRxWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg NGCzOXMzOTF5MEm4PC=>
KHYG-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXqxJO69VQ>? NFHwTHAzPCCq M1zQZnJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= MVSyNVE4ODl6OB?=
SNT-16 NGrz[ldCeG:ydH;zbZMhSXO|YYm= MkXzNUDPxE1? NVzJdZl{PiCq M1fNUGlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MWCyNVE4ODl6OB?=
Jurkat Mn\vRZBweHSxc3nzJGF{e2G7 Ml;hNUDPxE1? M3zPWVYhcA>? NHfhVnFKdmS3Y3XzJINmdGxiYYDvdJRwe2m| NVrNXItSOjFzN{C5PFg>
KAI-3 NETyfllCeG:ydH;zbZMhSXO|YYm= NXftW3cyOSEQvF2= M2\2XFYhcA>? MX;JcoR2[2W|IHPlcIwh[XCxcITvd4l{ MnSzNlEyPzB7OEi=
KHYG-1 NFfZZXRCeG:ydH;zbZMhSXO|YYm= NYDFR2NXOSEQvF2= MonEOkBp M{XCZmlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NXz2VnFzOjFzN{C5PFg>
SNT-13 NICwbWdCdnSrdnnyZYwhSXO|YYm= NEXRZ2QyKM7:TR?= M{TZO|I1KGh? M{\6NGlv\HWlZYOgcJl1cWNiaX7m[YN1cW:wIH;mJGVDXg>? NXT3b21LOjFzN{C5PFg>
SNT-16 M3HuXGFvfGm4aYLhcEBCe3OjeR?= M3S5OFEh|ryP M{LFNVI1KGh? NFficG9KdmS3Y3XzJIx6fGmlIHnu[oVkfGmxbjDv[kBGSlZ? MlfMNlEyPzB7OEi=
KAI-3 NGHLfHRCdnSrdnnyZYwhSXO|YYm= MVSxJO69VQ>? MkHLNlQhcA>? M1zUWWlv\HWlZYOgcJl1cWNiaX7m[YN1cW:wIH;mJGVDXg>? M1rONFIyOTdyOUi4
SNK-6 NELkT2lCdnSrdnnyZYwhSXO|YYm= MkDZNUDPxE1? MoX1NlQhcA>? NEH4RnFKdmS3Y3XzJIx6fGmlIHnu[oVkfGmxbjDv[kBGSlZ? Ml34NlEyPzB7OEi=
RAW 264.7 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXZSFRnOTByIH7N NV3m[FNKPDhiaB?= NUDj[5VQWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg Mmj5NlI1OjdzNUS=
A375 NXnhXo5{SXCxcITvd4l{KEG|c3H5 MX[xNEBvVQ>? NUX4NVhROjRiaB?= MnrBTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MVWyN|A4QTB6Mx?=
BLM NHHSWohCeG:ydH;zbZMhSXO|YYm= MnrYNVAhdk1? NX;4dGQ6OjRiaB?= NELpRWNKdmS3Y3XzJINmdGxiYYDvdJRwe2m| MnXnNlMxPzlyOEO=
A375 MmnWRZV1d3CqYXf5JGF{e2G7 MWGxNEBvVQ>? NHr3UXUyOiCq M{j6[Glv\HWlZYOg[o9zdWG2aX;uJI9nKGG3dH;wbIFod3OxbXXz MYmyN|A4QTB6Mx?=
BLM M4XPVWF2fG:yaHHnfUBCe3OjeR?= NIHZ[VIyOCCwTR?= MYOxNkBp M{Xidmlv\HWlZYOg[o9zdWG2aX;uJI9nKGG3dH;wbIFod3OxbXXz NUPT[HFQOjNyN{mwPFM>
H1299 NHfaOWFCeG:ydH;zbZMhSXO|YYm= MmDSPFAhdk1? NHj0NlgzPCCq NUKzVolwTE2VTx?= MXTT[Y5{cXSrenXzJG5US0yFIHPlcIx{KHSxIF3TR{1l\XKrdnXkJIlEQS2rbnT1Z4VlKGGyb4D0c5Nqew>? NUDVb2FOOjV|MkO2PVM>
Hut-78 MXLGeY5kfGmxbjDBd5NigQ>? MXSxNFAhdk1? M{H1b|I1KGh? M3ThdmROW09? MojKSI94dnKnZ4XsZZRmeyCWR1[t{tIyKGGwZDDJUE0yOCCneIDy[ZN{cW:w M3G2XFI2PjhzM{O1
H9 MYXGeY5kfGmxbjDBd5NigQ>? MXWxNFAhdk1? MUCyOEBp NXXmUYZHTE2VTx?= M3TZU2Rwf26{ZXf1cIF1\XNiVFfGMe6zOSCjbnSgTWwuOTFiZYjwdoV{e2mxbh?= NFLTbJEzPTZ6MUOzOS=>
HH NWOzSGluTnWwY4Tpc44hSXO|YYm= MVexNFAhdk1? MlvmNlQhcA>? MorYSG1UVw>? M3;V[IRwf26{ZXf1cIF1\XNiVFfGMe6zOSCjbnSgTWwuOTJiZYjwdoV{e2mxbh?= M4LPN|I2PjhzM{O1
Hut-78 MWnNbYdz[XSrb36gRZN{[Xl? NXrhOnZmOTByIH7N NVLLNmNxOjRiaB?= NFziW3FFVVOR M13ZenJm\HWlZYOgZ4VtdCCvaXfyZZRqd25iYomgPFDjiJN7MDW= M2X4VFI2PjhzM{O1
HH M3\GVm1q\3KjdHnvckBCe3OjeR?= M361PFExOCCwTR?= M2XlWlI1KGh? MXfEUXNQ MlHOVoVlfWOnczDj[YxtKG2rZ4LheIlwdiCkeTC4NQKBmzlzJR?= M1W3fFI2PjhzM{O1
U937 MWXGeY5kfGmxbjDBd5NigQ>? NUfUWFZFOTByIH7N NIPIbFY3KGh? M2TUXmlv\HWlZYOgTWwuQCCneIDy[ZN{cW:wIHnuJGxRWy2|dHnteYxifGWmIGW5N|chdWGlcn;wbIFo\XN? M3v1SFI2PzlzNEe3
human PBMC MWTGeY5kfGmxbjDBd5NigQ>? NUnLbGpxOTByIH7N NH3kblczPCCq M4rhNGlv\HWlZYOgTWwuQCC{ZXzlZZNm MWWyOVc6OTR5Nx?=
ES6 NX3WTY9RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILROGVKSzVyPUCuNFAzOSCwTR?= NVvuSFFsW0GQR1XS
SK-UT-1 Ml6wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUntenNDUUN3ME2wMlE3OyCwTR?= NXzjcoR3W0GQR1XS
SH-4 NIXFcphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1W2cGlEPTB;MD6xO|Mhdk1? Ml;FV2FPT0WU
TE-9 NITWWpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLJTWM2OD1yLkG4NkBvVQ>? MnO4V2FPT0WU
A253 MoHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PvUGlEPTB;MD6yNFghdk1? Mli2V2FPT0WU
no-10 Mn[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGe0[nRKSzVyPUCuNlEhdk1? NYW1NWwyW0GQR1XS
MMAC-SF M3f2cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrUWmJKSzVyPUCuNlE3KG6P MUfTRW5ITVJ?
A101D NIPwXG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnG4TWM2OD1yLkKyOUBvVQ>? M{\3UnNCVkeHUh?=
NTERA-S-cl-D1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHEb2RKSzVyPUCuNlQ{KG6P M3LiU3NCVkeHUh?=
8-MG-BA NV6yeHM5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHqUVhGUUN3ME2wMlI2KG6P M1;JOXNCVkeHUh?=
KNS-42 NH\1T3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nOc2lEPTB;MD6yOVghdk1? NUG5XYtDW0GQR1XS
LXF-289 M{jBfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLqW2JyUUN3ME2wMlI3QSCwTR?= M4HGOXNCVkeHUh?=
OVCAR-4 M1nFN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M323TmlEPTB;MD6yPFkhdk1? MXrTRW5ITVJ?
LOUCY NUjIUVA3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTBwMkmzJI5O NXjuRop4W0GQR1XS
BB65-RCC MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLIU2pKSzVyPUCuN|A1KG6P M4DWb3NCVkeHUh?=
D-542MG MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTBwM{K5JI5O MnrPV2FPT0WU
ONS-76 NHzEUJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TRNmlEPTB;MD6zN{BvVQ>? MnPyV2FPT0WU
BB30-HNC MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTBwM{O1JI5O M2fDVXNCVkeHUh?=
KS-1 NYrPVYk5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XGWmlEPTB;MD6zOEBvVQ>? M3\MbXNCVkeHUh?=
A388 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTBwM{W2JI5O NUTlVFl[W0GQR1XS
ES8 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PkUGlEPTB;MD60JI5O NI\HO21USU6JRWK=
MZ2-MEL MlLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDSTWM2OD1yLkSwO{BvVQ>? Ml;EV2FPT0WU
HCC2998 NUe5eZpqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjHVHBYUUN3ME2wMlQyOiCwTR?= NIPlfWNUSU6JRWK=
D-247MG NVPYfmlyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXwTWM2OD1yLkSxN{BvVQ>? M4HkWnNCVkeHUh?=
ACN NWLvbHZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETYXoNKSzVyPUCuOFE4KG6P M{fTUXNCVkeHUh?=
LB2518-MEL MnfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DrVWlEPTB;MD60NlUhdk1? MUXTRW5ITVJ?
ES1 NGfMc4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXPWXpKSzVyPUCuOFMhdk1? MnHJV2FPT0WU
HCE-T MofsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnHWW9LUUN3ME2wMlQ{QSCwTR?= NYjCcZQ3W0GQR1XS
OS-RC-2 MlzNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\ubYs4UUN3ME2wMlQ1KG6P NIPPeVhUSU6JRWK=
MFH-ino MnfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTxTWM2OD1yLkS0N{BvVQ>? NWexcpVbW0GQR1XS
OCUB-M NYnwZVA{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHXO|ZKSzVyPUCuOFQ4KG6P MUnTRW5ITVJ?
CP66-MEL M164UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fBemlEPTB;MD60O|Mhdk1? M2\LbHNCVkeHUh?=
LB771-HNC MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLUTWM2OD1yLkS3OEBvVQ>? MUnTRW5ITVJ?
DSH1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlviTWM2OD1yLkS4JI5O Mmq5V2FPT0WU
HUTU-80 NVfxVHdVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTBwNUOzJI5O NIraRYxUSU6JRWK=
CESS M2m3N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnYUGNNUUN3ME2wMlU{QCCwTR?= M2rGNHNCVkeHUh?=
NCI-H747 NELlZ4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTBwNUO5JI5O MWPTRW5ITVJ?
HT-144 NXrjXoFYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2q4W2lEPTB;MD61O|Yhdk1? M1yzeXNCVkeHUh?=
COLO-829 M1;IZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7LTWM2OD1yLk[xOEBvVQ>? MX3TRW5ITVJ?
A4-Fuk NHXnZmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPjTWM2OD1yLk[yN{BvVQ>? MnjwV2FPT0WU
GI-ME-N MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTWcG9pUUN3ME2wMlY{PCCwTR?= Ml[yV2FPT0WU
LB831-BLC MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTDNpVKSzVyPUCuOlQyKG6P MmTuV2FPT0WU
HOP-62 NVLUZnNsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TkV2lEPTB;MD62OFchdk1? M2DzZnNCVkeHUh?=
BB49-HNC MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPSVGdSUUN3ME2wMlY2OiCwTR?= MVvTRW5ITVJ?
D-336MG MoH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTBwNkW3JI5O NFHK[4ZUSU6JRWK=
TK10 NFT0WY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjhWGdKSzVyPUCuOlc6KG6P NVfo[GExW0GQR1XS
Ramos-2G6-4C10 NFvoS3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17YVWlEPTB;MD62PVMhdk1? NVfQd2VtW0GQR1XS
LB373-MEL-D NVnke3drT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrlb|FkUUN3ME2wMlchdk1? M{LlPHNCVkeHUh?=
SF126 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTieYFJUUN3ME2wMlcxOSCwTR?= MlHMV2FPT0WU
UACC-257 MnyyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2S1NWlEPTB;MD63NUBvVQ>? MUDTRW5ITVJ?
KINGS-1 MlvMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTBwN{KyJI5O NY\rPGc1W0GQR1XS
LS-513 MoC1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\HPYlKUUN3ME2wMlc{QSCwTR?= MVLTRW5ITVJ?
GI-1 MliwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLtTWM2OD1yLke2OEBvVQ>? MWrTRW5ITVJ?
ES7 MoDvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrLTWM2OD1yLke2OkBvVQ>? MU\TRW5ITVJ?
LB2241-RCC NVP6[JhHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfmWnRKSzVyPUCuPFA1KG6P MWPTRW5ITVJ?
D-263MG NFLEeoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTBwOEC3JI5O NEHmXmRUSU6JRWK=
SW684 NFjNc4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTBwOEKxJI5O Mm\ZV2FPT0WU
ML-2 NIj5bW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVv5XFZKUUN3ME2wMlgzOSCwTR?= MVLTRW5ITVJ?
SK-LMS-1 MnWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17ScGlEPTB;MD64OVQhdk1? MUHTRW5ITVJ?
TE-5 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrF[VFKSzVyPUCuPFY2KG6P MVHTRW5ITVJ?
QIMR-WIL NIHNenFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfwfGtKSzVyPUCuPFg6KG6P M1j1UXNCVkeHUh?=
NCI-H1355 M1XRfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnT1TWM2OD1yLki5OUBvVQ>? MVfTRW5ITVJ?
SNB75 NE[yVYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTBwOUGyJI5O MYTTRW5ITVJ?
RXF393 NFXoOWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXFeVhKSzVyPUCuPVE1KG6P M{fkOnNCVkeHUh?=
IST-MEL1 NELKd4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1Pv[2lEPTB;MD65NVchdk1? MV7TRW5ITVJ?
SF268 NUmwT3VQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;0OXFDUUN3ME2wMlkzOyCwTR?= NGPBXGdUSU6JRWK=
KALS-1 NYLiWFVQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTBwOUK1JI5O M{ntUnNCVkeHUh?=
HC-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTBwOUe1JI5O M4PvTXNCVkeHUh?=
SW872 NW\TSlNiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrGUnlHUUN3ME2wMlk6PiCwTR?= M3vTZ3NCVkeHUh?=
PSN1 Mlr5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlL0TWM2OD1zLkCxJI5O MX7TRW5ITVJ?
TE-1 NGD4UZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrnSGxyUUN3ME2xMlA{KG6P M4DYSnNCVkeHUh?=
TE-10 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTFwMEOgcm0> NHnBRZVUSU6JRWK=
RKO MoXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zUdmlEPTB;MT6wOkBvVQ>? MkDkV2FPT0WU
LC-2-ad MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXK5fo5[UUN3ME2xMlA5KG6P NFXhZ5FUSU6JRWK=
SK-MM-2 NVTne28yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTFwMEmgcm0> NXrUTmc3W0GQR1XS
VA-ES-BJ NF6zcpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;WW3VEUUN3ME2xMlA6KG6P MnzYV2FPT0WU
MZ7-mel NFS3VllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDVTWM2OD1zLkC5JI5O Mlr6V2FPT0WU
D-392MG NH3iVW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mor6TWM2OD1zLkGgcm0> NF;4Z|BUSU6JRWK=
CCRF-CEM M{fOdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTvTWRKSzVyPUGuNVMhdk1? M4HTe3NCVkeHUh?=
EM-2 NVPMbHJrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjOfGdKSzVyPUGuNVYhdk1? MUnTRW5ITVJ?
HAL-01 NX\RPHFLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPoS4l3UUN3ME2xMlE5KG6P NELJR4RUSU6JRWK=
TE-8 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLL[oFKSzVyPUGuNVkhdk1? Mn7DV2FPT0WU
NCI-H1882 M4m5dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jnUWlEPTB;MT6yJI5O MULTRW5ITVJ?
Daudi M3flW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEK4fJpKSzVyPUGuNlIhdk1? NHWwZ|RUSU6JRWK=
BL-41 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHITY5KSzVyPUGuNlUhdk1? NUXKR3RzW0GQR1XS
SR MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HxU2lEPTB;MT6yOUBvVQ>? NFHGWJlUSU6JRWK=
KM12 MnTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TSRWlEPTB;MT6yO{BvVQ>? NHPHUnFUSU6JRWK=
K5 Mkf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTFwMkigcm0> MVnTRW5ITVJ?
A3-KAW NH3adpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo[3TWM2OD1zLkK4JI5O MkXYV2FPT0WU
CMK NHzWeG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTFwMkmgcm0> MYnTRW5ITVJ?
Calu-6 Mo\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\NNmlEPTB;MT6yPUBvVQ>? NYXXT411W0GQR1XS
IST-SL2 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGO2cY5KSzVyPUGuN|Ehdk1? NEnIU5lUSU6JRWK=
OPM-2 NYTJdoR5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXyxbZpGUUN3ME2xMlM{KG6P NYXiNpBTW0GQR1XS
DU-4475 NYXMTYdmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUCwTHpvUUN3ME2xMlM3KG6P MYXTRW5ITVJ?
ECC12 MkW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrnTWM2OD1zLkO3JI5O Ml\ZV2FPT0WU
L-540 NX7QeJdzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zJfmlEPTB;MT6zO{BvVQ>? NHzUXVZUSU6JRWK=
CAS-1 NIXac4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2D3cmlEPTB;MT6zO{BvVQ>? MkfVV2FPT0WU
PF-382 MlXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rBVGlEPTB;MT60O{BvVQ>? NY\5RYduW0GQR1XS
LS-411N Ml;MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fLS2lEPTB;MT61N{BvVQ>? MVjTRW5ITVJ?
NCI-H69 M{LrXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHEVZh3UUN3ME2xMlU1KG6P M2ey[XNCVkeHUh?=
NB12 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HnUWlEPTB;MT61OkBvVQ>? NWXVU5VjW0GQR1XS
HEL NHTrcG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvuTWM2OD1zLk[xJI5O MYTTRW5ITVJ?
GCIY M3LRVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTFwNkKgcm0> M1fZOHNCVkeHUh?=
EHEB MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTFwNkegcm0> MXzTRW5ITVJ?
TGBC1TKB M1nzVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2Hrc2lEPTB;MT63NUBvVQ>? NXfnSld6W0GQR1XS
KURAMOCHI M1;5Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTFwN{Kgcm0> M{D6XHNCVkeHUh?=
U-266 MlTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHqxd|VKSzVyPUGuO|Yhdk1? MV3TRW5ITVJ?
LC4-1 NUS0N3NET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTFwN{mgcm0> MkXvV2FPT0WU
NCI-H2126 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDkTWM2OD1zLkigcm0> M3vHT3NCVkeHUh?=
NCI-H1092 NHnt[JdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFG0N2NKSzVyPUGuPEBvVQ>? NFXXUIJUSU6JRWK=
GB-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnYN3BKSzVyPUGuPFEhdk1? MYDTRW5ITVJ?
MV-4-11 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmP5TWM2OD1zLkiyJI5O NIjH[5BUSU6JRWK=
Becker NIW5RnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlv2TWM2OD1zLkizJI5O Mn3oV2FPT0WU
MPP-89 Mm\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIj0TG1KSzVyPUGuPFkhdk1? MVPTRW5ITVJ?
BE-13 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jjc2lEPTB;MT65N{BvVQ>? NVy0VpJSW0GQR1XS
697 M{O4OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDnUWlKSzVyPUGuPVkhdk1? M2\k[HNCVkeHUh?=
NKM-1 NYXMOYVET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jt[2lEPTB;MjDuUS=> MVHTRW5ITVJ?
NB13 NWjZcVkzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\ZTYlRUUN3ME2yJI5O MljBV2FPT0WU
LS-123 M3e5VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;0cYpKSzVyPUKuNFIhdk1? MlPqV2FPT0WU
NB17 M2j1fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPtR5pKSzVyPUKuNFQhdk1? NUXMU3diW0GQR1XS
LAN-6 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1r5W2lEPTB;Mj6wOUBvVQ>? NHLJNY5USU6JRWK=
EW-24 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\i[XY2UUN3ME2yMlA5KG6P M2TkZ3NCVkeHUh?=
NOS-1 NFjDT|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFO1O2dKSzVyPUKuNVEhdk1? NWWySmRWW0GQR1XS
BL-70 NF;SV3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\mdVh4UUN3ME2yMlEzKG6P NXnURopOW0GQR1XS
GT3TKB NF7FbVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTtTWM2OD1{LkGyJI5O Mn7BV2FPT0WU
HH M1HBWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfMTWM2OD1{LkGzJI5O M{TKc3NCVkeHUh?=
KE-37 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPPfGs3UUN3ME2yMlE{KG6P Mn\WV2FPT0WU
MOLT-4 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3pTWM2OD1{LkGzJI5O NUDXe25GW0GQR1XS
EKVX M1X2Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXtfnRKSzVyPUKuNVQhdk1? NX;v[5JjW0GQR1XS
KGN MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MluxTWM2OD1{LkG1JI5O MX7TRW5ITVJ?
ES4 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTJwMU[gcm0> NWfwXYc{W0GQR1XS
SJSA-1 NVHNTm1lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fpR2lEPTB;Mj6yNUBvVQ>? NEfGd5BUSU6JRWK=
KMOE-2 NWTlWZdqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTJwMkOgcm0> NYX0NpFjW0GQR1XS
NB5 NYDZPIp{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTkTWM2OD1{LkK3JI5O MnzYV2FPT0WU
BC-1 MoL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jvPWlEPTB;Mj6zNUBvVQ>? NVzaepZoW0GQR1XS
NB10 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfrfGtKSzVyPUKuN|Ihdk1? MYrTRW5ITVJ?
RPMI-8226 M2rvRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jUVmlEPTB;Mj6zOUBvVQ>? NHK4W25USU6JRWK=
SCC-3 M{\zZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfBTWM2OD1{LkO3JI5O MXnTRW5ITVJ?
ARH-77 Ml3qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHLTWM2OD1{LkO4JI5O MYjTRW5ITVJ?
NCI-H748 NF\Fc|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3v4WmlEPTB;Mj6zPUBvVQ>? Mn3OV2FPT0WU
KU812 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorLTWM2OD1{LkSyJI5O NYjGWoFYW0GQR1XS
NCI-H64 NGT1PY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlP1TWM2OD1{LkS0JI5O NFLEcY9USU6JRWK=
NB69 NFz5RZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3Xtb2lEPTB;Mj60OkBvVQ>? MU\TRW5ITVJ?
KNS-81-FD NVu2RWIxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPqXJhKSzVyPUKuOFghdk1? MXPTRW5ITVJ?
LB1047-RCC MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDSUoZKSzVyPUKuOVchdk1? NFPTOnlUSU6JRWK=
EB-3 Ml3TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTJwNk[gcm0> M{PLWnNCVkeHUh?=
Mo-T M3n4[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4iz[2lEPTB;Mj63OEBvVQ>? MlrMV2FPT0WU
EW-16 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFroN|hKSzVyPUKuO|Uhdk1? MnjsV2FPT0WU
CTV-1 MljMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLiZm9jUUN3ME2yMlghdk1? M3rwNnNCVkeHUh?=
ETK-1 MnTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3i3WGlEPTB;Mj64OEBvVQ>? MljOV2FPT0WU
C2BBe1 NX3CN4JCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;2bo9KSzVyPUKuPFkhdk1? NXPVc5hiW0GQR1XS
MOLT-16 Ml\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPSTWM2OD1{Lki5JI5O M3u1cnNCVkeHUh?=
SW954 M{nEVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTDemNyUUN3ME2yMlkhdk1? M4\Jd3NCVkeHUh?=
HT MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTNwMEKgcm0> M1LheXNCVkeHUh?=
KARPAS-299 MkDtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTNwME[gcm0> Mm\qV2FPT0WU
MONO-MAC-6 NWjw[VZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTNwMTDuUS=> M3HNNnNCVkeHUh?=
CGTH-W-1 Ml7SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTNwMTDuUS=> NUn6WWYxW0GQR1XS
SK-PN-DW MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;wcGlEPTB;Mz6xOEBvVQ>? NW[wbpZDW0GQR1XS
CW-2 MmjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTNwMkGgcm0> NHfwUYtUSU6JRWK=
SK-N-DZ MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnuT21KSzVyPUOuNlYhdk1? NGS1ZopUSU6JRWK=
NEC8 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYSxc5lOUUN3ME2zMlM2KG6P MWLTRW5ITVJ?
LB996-RCC NIrNeHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvFRYxKSzVyPUOuOEBvVQ>? NYC3eJV7W0GQR1XS
DB NXLXeZpmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW[0UHlsUUN3ME2zMlQyKG6P M1LKc3NCVkeHUh?=
TE-15 NXnJ[XVIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PQeWlEPTB;Mz60N{BvVQ>? MVHTRW5ITVJ?
COR-L88 NEjtRmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjIXHdKSzVyPUOuOFchdk1? MUnTRW5ITVJ?
LAMA-84 M3\rbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vSdWlEPTB;Mz60PUBvVQ>? NVvXZXVZW0GQR1XS
MEG-01 MnzxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LJdWlEPTB;Mz60PUBvVQ>? NWLyNIV2W0GQR1XS
LOXIMVI M1HJZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTNwNTDuUS=> Mn;PV2FPT0WU
RPMI-8402 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPLT2pKSzVyPUOuOUBvVQ>? MoG3V2FPT0WU
KARPAS-45 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDWfXNKSzVyPUOuOVQhdk1? MmrRV2FPT0WU
HCC1187 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7RTWM2OD1|LkW0JI5O NEjmV5lUSU6JRWK=
MZ1-PC NYDoSnJPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfjRmxKSzVyPUOuOVQhdk1? MXvTRW5ITVJ?
no-11 M3POcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LxcWlEPTB;Mz61OUBvVQ>? NV36VYNWW0GQR1XS
EVSA-T MmDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrPWI1XUUN3ME2zMlYhdk1? NGHYTpdUSU6JRWK=
DJM-1 NV\1dI9NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTNwNkOgcm0> NIDne25USU6JRWK=
COLO-684 NGPBeJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTNwNk[gcm0> MYLTRW5ITVJ?
NMC-G1 NHjPUlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLnV3dKSzVyPUOuOlghdk1? MkfaV2FPT0WU
LC-1F MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnO[mJ2UUN3ME2zMlc1KG6P M1;iT3NCVkeHUh?=
RL95-2 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\1c3JJUUN3ME2zMlc6KG6P MXjTRW5ITVJ?
COLO-320-HSR NH\EOXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTNwOUKgcm0> MVLTRW5ITVJ?
RCC10RGB NXzsPWY{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4KwWmlEPTB;Mz65N{BvVQ>? MVHTRW5ITVJ?
HD-MY-Z NGmxZ|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWO1SoNOUUN3ME2zMlk{KG6P MY\TRW5ITVJ?
NCI-H2141 NEK0SGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PPRWlEPTB;ND6wOUBvVQ>? M161NHNCVkeHUh?=
K-562 NFnX[2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlv4TWM2OD12LkGyJI5O MVjTRW5ITVJ?
NCI-H1648 NXrpU5kzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTRwMUOgcm0> MkPoV2FPT0WU
OMC-1 MmrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHBTWM2OD12LkG4JI5O NWDUcI41W0GQR1XS
LB647-SCLC NHXYOo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\EUphKSzVyPUSuNlIhdk1? NWDHbms2W0GQR1XS
TE-12 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3u4emlEPTB;ND6yOUBvVQ>? M4XhXXNCVkeHUh?=
NOMO-1 NWLrZ4hnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDTTWM2OD12LkOzJI5O MVrTRW5ITVJ?
Raji MlznS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTRwNE[gcm0> NELj[lZUSU6JRWK=
NALM-6 Ml\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfLb41KSzVyPUSuOFkhdk1? MWHTRW5ITVJ?
HL-60 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfJTWM2OD12Lk[3JI5O MVjTRW5ITVJ?
IST-SL1 NETNb29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrLeVNKUUN3ME20MlY5KG6P NIXGbmZUSU6JRWK=
MHH-PREB-1 NFnVUndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XUNmlEPTB;ND64OkBvVQ>? Ml\pV2FPT0WU
MHH-NB-11 M1\IS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTRwOUGgcm0> NUK1dIVmW0GQR1XS
JiyoyeP-2003 NETjTXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;oTWM2OD13IH7N M4jVXnNCVkeHUh?=
SBC-1 NHznfVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mln0TWM2OD13LkCxJI5O NIfhOXFUSU6JRWK=
CHP-126 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XuNWlEPTB;NT6wOkBvVQ>? MmTFV2FPT0WU
LU-139 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1P0T2lEPTB;NT6xN{BvVQ>? NYfuOow5W0GQR1XS
NCI-SNU-5 NVLiNoFwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\zdGlEPTB;NT6xO{BvVQ>? NHLjd3ZUSU6JRWK=
SW962 NWLVTldzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTVwMkGgcm0> MmDtV2FPT0WU
EW-1 NGnwOmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fJSmlEPTB;NT6zNUBvVQ>? MUfTRW5ITVJ?
NCI-H1417 NWqzeGJrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTVwNUGgcm0> NIPabG9USU6JRWK=
LU-65 NUHlc21ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2ew[2lEPTB;NT64OEBvVQ>? M4LFeXNCVkeHUh?=
D-502MG M13mfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHi0b29KSzVyPU[uN|chdk1? NUXDVXhbW0GQR1XS
BC-3 MkTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLne4RFUUN3ME22MlYyKG6P MV\TRW5ITVJ?
GDM-1 NEXqWYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PhUGlEPTB;Nj63O{BvVQ>? M4nmdnNCVkeHUh?=
NCI-H2196 Ml3lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLGTWM2OD14Lkigcm0> NH:3VmxUSU6JRWK=
NB1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHibGZKSzVyPU[uPFghdk1? MknBV2FPT0WU
NCI-H345 MmrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HVNmlEPTB;Nz6yJI5O Mlf1V2FPT0WU
SU-DHL-1 M3LVUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nBSGlEPTB;Nz6yOEBvVQ>? NFfzT3FUSU6JRWK=
JVM-2 MnztS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1:4ZmlEPTB;Nz6yPEBvVQ>? MoT0V2FPT0WU
LU-134-A MoLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1K1bWlEPTB;Nz6zPUBvVQ>? NGj0O3NUSU6JRWK=
NCI-H1694 NWH2NFJTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjPfWdKSzVyPUeuOVghdk1? NFXvfJdUSU6JRWK=
NCI-SNU-16 M4H2N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETte4hKSzVyPUeuOlUhdk1? MXrTRW5ITVJ?
L-363 MmrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7CVYtKSzVyPUeuO{BvVQ>? MmLRV2FPT0WU
KG-1 M4jQWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULuZXdpUUN3ME23Mlk1KG6P MmLpV2FPT0WU
MN-60 M1m1U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW[0RnVFUUN3ME24MlE1KG6P Mo\iV2FPT0WU
NB6 MlXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rjWmlEPTB;OD60PEBvVQ>? NEKyfmRUSU6JRWK=
MLMA M{nhbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XldmlEPTB;OD64OUBvVQ>? M3PuVHNCVkeHUh?=
ATN-1 M{HpUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\xSZRKSzVyPUiuPFkhdk1? M3TuSHNCVkeHUh?=
SK-NEP-1 MkLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rlcGlEPTB;OT6wNUBvVQ>? MmGxV2FPT0WU
DMS-114 NWTNXJgzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLvS4xbUUN3ME25MlYzKG6P MljzV2FPT0WU
CTB-1 NFjrbXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvzOmRKSzVyPUmuOlchdk1? Mn3SV2FPT0WU
NCI-H2081 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTFyLkC5JI5O M4frO3NCVkeHUh?=
ES5 NYnaNXJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmS2TWM2OD1zMD6zPEBvVQ>? M4HSdnNCVkeHUh?=
HCC1599 NUO3eoI2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\5TY5KSzVyPUGxMlkyKG6P NGDqdXRUSU6JRWK=
NCI-H23 M2XoZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTF{LkGyJI5O MkHOV2FPT0WU
NCI-H1581 M1LKOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTyUIZlUUN3ME2xNk4zQCCwTR?= Ml3ZV2FPT0WU
JVM-3 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LXemlEPTB;MUKuPVkhdk1? M2fpc3NCVkeHUh?=
NCI-SNU-1 NE[4eFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTF|LkG5JI5O MkPEV2FPT0WU
NB7 NYLVSGxWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTF3LkmyJI5O M{DPbHNCVkeHUh?=
JAR M2\2[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTF4LkGzJI5O MkDCV2FPT0WU
TGW NUjiZ|N{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTF4LkS4JI5O M3S4cHNCVkeHUh?=
U-87-MG NYTSZ5ZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7XfZNKSzVyPUG2Mlc3KG6P MWrTRW5ITVJ?
NCI-H1436 NEHhfplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWf0[Jd4UUN3ME2xO{4xOSCwTR?= MXnTRW5ITVJ?
GOTO MmHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnkPZhKSzVyPUG3MlA3KG6P NGThVYNUSU6JRWK=
COLO-800 NF;LPWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXTXodKSzVyPUG3MlY1KG6P MXXTRW5ITVJ?
MFM-223 NIDvem5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3yxSGlEPTB;MUeuPVEhdk1? MkfUV2FPT0WU
EW-18 M4rad2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoWxTWM2OD1zNz65OkBvVQ>? NGj4bVlUSU6JRWK=
NB14 M{HneWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2KxW2lEPTB;MUeuPVghdk1? MX3TRW5ITVJ?
EB2 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXadFFKSzVyPUG4MlA5KG6P M{TDVnNCVkeHUh?=
EoL-1- NVjWb5pGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnmyTWM2OD1zOD6zNUBvVQ>? MojlV2FPT0WU
NCCIT MonSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TFfWlEPTB;MUiuN|Yhdk1? MnHmV2FPT0WU
DG-75 NUn0ZY1oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXQW25KSzVyPUG4MlYyKG6P MXzTRW5ITVJ?
HCC2218 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTF7LkWgcm0> NGi3NXhUSU6JRWK=
TE-6 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHFTWM2OD1{MD6wPEBvVQ>? NWjjOY44W0GQR1XS
SF539 M37qXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrpWVFKSzVyPUKwMlY4KG6P NXj5PYt1W0GQR1XS
NCI-H446 NIG3NnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLTTWM2OD1{MT6xPEBvVQ>? MlzRV2FPT0WU
IST-MES1 NFLVRotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\BTWM2OD1{Mj63O{BvVQ>? NFGzNVZUSU6JRWK=
NCI-H82 NWmxUo1LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH61cFdKSzVyPUKzMlAzKG6P M2K0c3NCVkeHUh?=
HCC2157 NHXGNm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoK4TWM2OD1{Mz6xN{BvVQ>? M4PtRnNCVkeHUh?=
EW-12 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELvZW9KSzVyPUKzMlE4KG6P NXK4UGxCW0GQR1XS
SIMA NGDISpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTJ|LkO4JI5O NHfmR2tUSU6JRWK=
DOHH-2 NV25fYJXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUn4b|VrUUN3ME2yN{41PSCwTR?= NWTSWJRrW0GQR1XS
IM-9 M4G5ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7Rb5ZKSzVyPUKzMlU1KG6P M{LBfXNCVkeHUh?=
EC-GI-10 NYny[HJTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13HR2lEPTB;MkSuNlMhdk1? NULvOZk3W0GQR1XS
HDLM-2 M{PDb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHv4Oo9KSzVyPUK0MlU1KG6P NILQS|FUSU6JRWK=
LS-1034 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rWUmlEPTB;MkWuO|Uhdk1? M1i2cHNCVkeHUh?=
REH MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TpW2lEPTB;Mk[uOFEhdk1? M4LiOnNCVkeHUh?=
LU-165 NWXNd5RtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTJ4LkeyJI5O NU\Te|NoW0GQR1XS
NH-12 NF7KNIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2f3R2lEPTB;MkeuOlchdk1? MYfTRW5ITVJ?
WSU-NHL NXjHSlIyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXz0[IhLUUN3ME2yPE4{QSCwTR?= M{POS3NCVkeHUh?=
ECC4 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfjNWw3UUN3ME2yPE44QSCwTR?= NEHhbJJUSU6JRWK=
OCI-AML2 M4PBNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPNdWtKSzVyPUK5MlY6KG6P NHf3[FRUSU6JRWK=
EW-3 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfVTWM2OD1|MD61PUBvVQ>? MUXTRW5ITVJ?
NCI-H526 MmTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTN{LkW0JI5O M{WxOHNCVkeHUh?=
NCI-H719 NFrsXJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI[xd3pKSzVyPUO0MlMyKG6P MlfiV2FPT0WU
KARPAS-422 NIfwe4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\EW3VtUUN3ME2zOU4xPCCwTR?= M1PuXXNCVkeHUh?=
SK-MEL-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3:5OWlEPTB;M{WuNVchdk1? NFjHSnNUSU6JRWK=
ES3 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTN3LkG5JI5O MXXTRW5ITVJ?
UACC-812 M{LtRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTN3LkS0JI5O NFPMUnJUSU6JRWK=
C8166 NFjEUoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PCdWlEPTB;M{WuO{BvVQ>? MU\TRW5ITVJ?
MDA-MB-134-VI NYHNTGczT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXUTWM2OD1|NT64O{BvVQ>? MlvhV2FPT0WU
D-283MED MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPpdmZEUUN3ME2zO{44QSCwTR?= MmrlV2FPT0WU
SHP-77 MnP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M36xN2lEPTB;M{iuNFMhdk1? M332UnNCVkeHUh?=
NCI-H2227 NVnOVWx5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7wd2ZRUUN3ME20NE41QSCwTR?= MonXV2FPT0WU
SKM-1 NVeyXldPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rvfWlEPTB;NEKuOlMhdk1? NY\qZnpzW0GQR1XS
L-428 M3vHfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\mOFZKSzVyPUSzMlg3KG6P M1PTU3NCVkeHUh?=
RPMI-6666 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGThVIhKSzVyPUS1Mlg6KG6P Ml7mV2FPT0WU
NCI-H716 NXTNO|lXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYizTnF7UUN3ME20PE45OSCwTR?= MnvKV2FPT0WU
DMS-79 M4rrc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTVyLkexJI5O M2[0Z3NCVkeHUh?=
RS4-11 M2m0Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HWcmlEPTB;NUCuPFghdk1? M3zMOHNCVkeHUh?=
NCI-H720 NV76eIpiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHJSZBFUUN3ME21NU4yOSCwTR?= MmH1V2FPT0WU
MC-CAR NI\lVWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTVzLkWyJI5O NH3TcIhUSU6JRWK=
TALL-1 M1XmfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7DOZFKSzVyPUWzMlkyKG6P NYWwUZpKW0GQR1XS
NCI-N87 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPCTWM2OD13ND6xPEBvVQ>? MUfTRW5ITVJ?
P30-OHK Mnu3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTV2Lk[xJI5O Mon5V2FPT0WU
LP-1 MnvlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrnPYE4UUN3ME22NU4zQCCwTR?= MWrTRW5ITVJ?
YT NEjOcmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXUSI5lUUN3ME22NU45KG6P MULTRW5ITVJ?
MRK-nu-1 M4\BfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn33TWM2OD14MT64NkBvVQ>? NGXrWnZUSU6JRWK=
BT-474 M3G0Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXVUGxsUUN3ME22OUBvVQ>? NXfVU3FHW0GQR1XS
NCI-H322M MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn2xTWM2OD14Nj6xNUBvVQ>? MXTTRW5ITVJ?
NCI-H128 MofFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfRXmRVUUN3ME23OE44PyCwTR?= MXHTRW5ITVJ?
KMS-12-PE M{Lvemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4OxbGlEPTB;N{[uNlQhdk1? NWGx[HU6W0GQR1XS
KP-N-YS MmnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrHTpY3UUN3ME23Ok44PCCwTR?= NVrTTXY2W0GQR1XS
ALL-PO M1LZUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTd5Lk[2JI5O NY\BR2tIW0GQR1XS
EW-13 NYDaWYF3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlS4TWM2OD15Nz63OkBvVQ>? MYPTRW5ITVJ?
EW-11 MnfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrDOVN4UUN3ME23PE42OiCwTR?= MV\TRW5ITVJ?
SK-N-FI NGrGbGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;KSXdKSzVyPUiwMlIhdk1? NInScHFUSU6JRWK=
CAL-148 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRThzLki0JI5O NWDiR|NxW0GQR1XS
RL NEi0NmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\US2lEPTB;OE[uNFkhdk1? MVHTRW5ITVJ?
AM-38 NVPDfoE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTh6LkC4JI5O NGC4V2NUSU6JRWK=
RH-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTl7Lki1JI5O Ml3lV2FPT0WU
NCI-H1770 NILWeJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfpTWM2OD1zMEKuOFkhdk1? M4S5NHNCVkeHUh?=
SIG-M5 Mn;SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHG2TYlKSzVyPUGwOU4xPiCwTR?= Ml;yV2FPT0WU
GR-ST NUfwc2hrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTFzMz6zOEBvVQ>? NIrmZZhUSU6JRWK=
ST486 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTFzND6wOkBvVQ>? M3GwOHNCVkeHUh?=
NCI-H1650 NEjGSXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PhemlEPTB;MUG1MlI6KG6P MWHTRW5ITVJ?
MHH-CALL-2 NYnme4puT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jp[GlEPTB;MUG1Mlchdk1? MmjmV2FPT0WU
BV-173 NXHQOoUzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37kNmlEPTB;MUKyMlcyKG6P M1PpOXNCVkeHUh?=
MC116 M1:w[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYftVpMyUUN3ME2xOFgvQDVibl2= MmLzV2FPT0WU
NCI-H524 NYrOTYNJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\MUWRKSzVyPUG1PU4yKG6P M1zTVXNCVkeHUh?=
SCLC-21H NHPWe2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHsTWM2OD1zNUmuOFEhdk1? MV3TRW5ITVJ?
NCI-H1304 MnTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zrTGlEPTB;MU[5MlIyKG6P Ml6zV2FPT0WU
NCI-H510A M2rrZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXWS3R6UUN3ME2xPFUvOzdibl2= NUPodHJXW0GQR1XS
NCI-H209 NWHYVlJiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrETWM2OD1zOU[uOVIhdk1? NHi1XlZUSU6JRWK=
KM-H2 NXnPbWJuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXf2W5RiUUN3ME2xPVcvODVibl2= NHzod49USU6JRWK=
NCI-H1395 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3K5RWlEPTB;MkGwMlE{KG6P NUTxNYN4W0GQR1XS
NCI-H1155 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\XU3dKSzVyPUKzNE4{OiCwTR?= NGjhdmVUSU6JRWK=
COR-L279 M{O0SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLzR2Z4UUN3ME2yOVIvOTdibl2= MUXTRW5ITVJ?
NCI-H1299 NXTU[W1pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3O1ZmlEPTB;Mk[xMlcyKG6P M2j0ZXNCVkeHUh?=
EW-22 NH3QXXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2iz[2lEPTB;Mk[zMlc2KG6P NFXjbW9USU6JRWK=
SK-MEL-2 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzRWGlYUUN3ME2yPFEvQSCwTR?= NYnuNVFWW0GQR1XS
KASUMI-1 Mmn0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTJ6Mz6wOUBvVQ>? Mm\OV2FPT0WU
NCI-H187 NFXqbWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDwRWFKSzVyPUK4O{4xQCCwTR?= NXHyW5JbW0GQR1XS
NCI-H2171 Mnz6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlroTWM2OD1{OEiuPVIhdk1? MlXwV2FPT0WU
LNCaP-Clone-FGC M4LINGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTJ7NT6yOkBvVQ>? MmfFV2FPT0WU
NCI-H1522 NGLyZoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTNyNz6wOUBvVQ>? MY\TRW5ITVJ?
SCH Ml\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnrO5FIUUN3ME2zNlIvOjJibl2= M3PQWnNCVkeHUh?=
THP-1 MmP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XPWGlEPTB;M{KyMlYhdk1? M2fyU3NCVkeHUh?=
SNU-C1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLZTWM2OD1|NkKuNFkhdk1? MomwV2FPT0WU
CA46 NXe0UHlpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPhZlRTUUN3ME2zO|MvPjNibl2= NYT4cmhrW0GQR1XS
NCI-H1963 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HHVGlEPTB;M{i2MlE6KG6P NXTt[JZVW0GQR1XS
DEL NF;NNYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnhS|NKSzVyPUO5NU4zPyCwTR?= MkjaV2FPT0WU
TUR MmW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTN7Nj62NUBvVQ>? MV;TRW5ITVJ?
NCI-H226 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHuTWM2OD12MEOuNlMhdk1? M1G3fHNCVkeHUh?=
COLO-668 M{X2PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfTeHdKSzVyPUSwN{42PyCwTR?= Mkn5V2FPT0WU
CPC-N NFLBNIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTRyMz63O{BvVQ>? NFvaPGNUSU6JRWK=
NCI-H889 NFfFVIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHztXY9KSzVyPUS2NU46OiCwTR?= NXz4TJBbW0GQR1XS
J-RT3-T3-5 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYq3dpVVUUN3ME21N|IvPTdibl2= M3zuWXNCVkeHUh?=
MSTO-211H MmnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vwSmlEPTB;NUe0MlI3KG6P MmPWV2FPT0WU
SCC-15 NV7qZlNMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2P0PWlEPTB;Nk[3MlQ4KG6P NXHj[2lZW0GQR1XS
SUP-T1 MnLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fLVGlEPTB;Nki2MlA1KG6P M4PiTnNCVkeHUh?=
DMS-153 NY\0c4l1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1:yU2lEPTB;N{S2Mlg{KG6P NVzLeIRSW0GQR1XS
MS-1 M3jWUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoK2TWM2OD15NUmuOFIhdk1? M33hOHNCVkeHUh?=
TC-YIK MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HLbmlEPTB;N{ixMlAyKG6P NFTyeolUSU6JRWK=
RPMI-8866 NFHWOZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnsTWM2OD1zMEC2MlI5KM7:TR?= MWTTRW5ITVJ?
KY821 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\ITGtKSzVyPUGwN|YvODRizszN MUfTRW5ITVJ?
P31-FUJ NF\vcVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGH5WYZKSzVyPUGxNVIvPzVizszN MlfhV2FPT0WU
COLO-824 NVfm[ZczT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\1VFFCUUN3ME2xNlYyNjd6IN88US=> MmDmV2FPT0WU
U-698-M MkPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYG3VFhNUUN3ME2yNlYzNjF3IN88US=> M1jwZXNCVkeHUh?=
TE-441-T MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTsT5JKSzVyPUK1NlEvPyEQvF2= M1zOWXNCVkeHUh?=
IMR-5 MnPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTITWM2OD1|NEC5MlYzKM7:TR?= NF;Vd25USU6JRWK=
NCI-H1838 NGXMN2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLycpJKSzVyPUSxPFYvOzJizszN M1ruOHNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo The anticancer effects of bortezomib as a single agent have been demonstrated in xenograft models of multiple myeloma, adult T-cell leukemia, lung, breast, prostate, pancreatic, head and neck, and colon cancer, and in melanoma. [2] Oral bortezomib 1.0 mg/ kg daily for 18 days causes tumor growth delays, as well as a decrease in the number of metastases in the Lewis lung cancer model. Bortezomib at a single dose of up to 5 mg/kg significantly decreased the surviving fraction of breast tumor cells. Bortezomib 1.0 mg/kg administrated weekly for 4 weeks reduces tumor growth by 60% in murine xenograft models of prostate cancer. 1.0 mg/kg Bortezomib administration for 4 weeks results in a 72% or 84% reduction in pancreatic cancer murine xenografts growth, as well as an increase in tumor cell apoptosis. 1.0 mg/kg Bortezomib treatment results in significant inhibition of human plasmacytoma xenograft growth, increase in tumor cells apoptosis and overall survival, and a decrease in tumor angiogenesis. [3]

Protocol

Kinase Assay:

[4]

+ Expand

Kinetic Methods:

In a typical kinetic run, 2.00 mL of assay buffer (20 mM HEPES, 0.5 mM EDTA, 0.035% SDS, pH 7.8) and Suc-Leu-Leu-Val-Tyr-AMC in DMSO are added to a 3 mL fluorescence cuvette, and the cuvette is placed in the jacketed cell holder of a fluorescence spectrophotometer. Reaction temperature is maintained at 37℃ by a circulating water bath. After the reaction solution has reached thermal equilibrium (5 minutes), 1 μL−10 μL of the stock enzyme solution is added to the cuvette. Reaction progress is monitored by the increase in fluorescence emission at 440 nm (λex= 380 nm) that accompanies cleavage of AMC from peptide-AMC substrates.
Cell Research:

[5]

+ Expand
  • Cell lines: Human multiple myeloma cells line U266
  • Concentrations: ~10 μM
  • Incubation Time: 2 days
  • Method:

    The inhibitory effect of Bortezomib on cell growth is assessed by measuring MTT dye absorbance of the cells. Cells from 48-hour cultures are pulsed with 10 μL of 5 mg/mL MTT to each well for the last 4 hour of 48-hour cultures, followed by 100 μL of isopropanol containing 0.04 N HCl. Absorbance is measured at 570 nm using a spectrophotometer.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: Human plasmacytoma xenografts RPMI 8226
  • Formulation: Saline
  • Dosages: 1 mg/kg
  • Administration: i.v. twice weekly for 4 weeks, then once weekly
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 76 mg/mL (197.79 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 2% DMSO+30% PEG 300+ddH2O 5mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 384.24
Formula

C19H25BN4O4

CAS No. 179324-69-7
Storage powder
Synonyms LDP-341, MLM341

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01891968 Completed Leukemia M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc. August 7, 2013 Phase 2
NCT01445405 Completed Carcinoma, Squamous|Head and Neck Cancer|Oral Cancer|Laryngeal Cancer|Pharyngeal Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 5, 2008 Phase 1
NCT02211755 Recruiting Neoplasms|Myelodysplastic Syndromes National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 30, 2014 Phase 1
NCT02654990 Recruiting Multiple Myeloma Novartis Pharmaceuticals|Novartis April 27, 2016 Phase 2
NCT00011778 Completed Squamous Cell Carcinoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 22, 2001 Phase 1
NCT02658396 Withdrawn Multiple Myeloma|Multiple Myeloma in Relapse|Refractory Multiple Myeloma Dana-Farber Cancer Institute|Genus Oncology, LLC|National Institutes of Health (NIH) June 2017 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Proteasome Signaling Pathway Map

Proteasome Inhibitors with Unique Features

Related Proteasome Products

Tags: buy Bortezomib (PS-341) | Bortezomib (PS-341) supplier | purchase Bortezomib (PS-341) | Bortezomib (PS-341) cost | Bortezomib (PS-341) manufacturer | order Bortezomib (PS-341) | Bortezomib (PS-341) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID